Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of clarifying the BPC 157 TB 500 FDA situation since it's getting garbled in basically every thread : r Biohackers FDA's Bulks List: Section 503A FDA Set to Review Peptide Access for Compounding Pharmacies Drug Topics Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #